ALLMedicine™ Cardioversion Center

Feb 26th, 2021 - Current guidelines recommend electrical cardioversion (ECV) in patients with atrial fibrillation (AF) after at least 3 weeks of adequate non-vitamin K antagonist oral anticoagulant (NOAC) treatment without prior transesophageal echocardiography (T...

Feb 25th, 2021 - The risk of ventricular arrhythmias in patients on QT prolonging drugs is indicated to be increased early after cardioversion (CV) of atrial fibrillation (AF) to sinus rhythm (SR). Sotalol, used to prevent AF relapse, prolongs cardiac repolarizati...

Feb 7th, 2021 - Atrial fibrillation (AF) is rarely found in newborns and infants. It is usually associated with some underlying diseases and presents as tachyarrhythmia. Here, we describe a case of AF in a preterm neonate. Paroxysmal AF and multifocal atrial tach...

Jan 31st, 2021 - The electrocardiogram and various echocardiography modalities are important risk markers for atrial fibrillation (AF). Electrocardiographic criteria of left atrial enlargement, advanced interatrial block, and PR-interval prolongation are atrial ri...

Jan 31st, 2021 - Obstructive sleep apnea (OSA) creates a complex and dynamic substrate for atrial fibrillation (AF), which is characterized by structural remodeling as a result of long-term OSA as well as transient and acute apnea-associated transient atrial elect...

Nov 8th, 2018 - The Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in atrial fibrillation (AF) management. This 2018 Focuse...

Sep 19th, 2015 - 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion).|2015|Zipes...

Sep 9th, 2015 - Rivaroxaban, a new oral anticoagulant, has been approved in many countries and its everyday use in clinical practice is increasing. Thus, the chances for an emergency physician to encounter rivaroxaban-treated patients in emergency situations have...

Oct 19th, 2010 - European Resuscitation Council Guidelines for Resuscitation 2010 Section 3. Electrical therapies: automated external defibrillators, defibrillation, cardioversion and pacing.|2010|Deakin CD,Nolan JP,Sunde K,Koster RW,|therapy,methods,standards,ins...

Feb 26th, 2021 - Current guidelines recommend electrical cardioversion (ECV) in patients with atrial fibrillation (AF) after at least 3 weeks of adequate non-vitamin K antagonist oral anticoagulant (NOAC) treatment without prior transesophageal echocardiography (T...

Feb 25th, 2021 - The risk of ventricular arrhythmias in patients on QT prolonging drugs is indicated to be increased early after cardioversion (CV) of atrial fibrillation (AF) to sinus rhythm (SR). Sotalol, used to prevent AF relapse, prolongs cardiac repolarizati...

Feb 7th, 2021 - Atrial fibrillation (AF) is rarely found in newborns and infants. It is usually associated with some underlying diseases and presents as tachyarrhythmia. Here, we describe a case of AF in a preterm neonate. Paroxysmal AF and multifocal atrial tach...

Jan 31st, 2021 - The electrocardiogram and various echocardiography modalities are important risk markers for atrial fibrillation (AF). Electrocardiographic criteria of left atrial enlargement, advanced interatrial block, and PR-interval prolongation are atrial ri...

Jan 31st, 2021 - Obstructive sleep apnea (OSA) creates a complex and dynamic substrate for atrial fibrillation (AF), which is characterized by structural remodeling as a result of long-term OSA as well as transient and acute apnea-associated transient atrial elect...

Nov 16th, 2020 - Two studies published in the New England Journal of Medicine compare ablation to antiarrhythmic drugs early in the course of atrial fibrillation (AF). Their "positive" results scare me; AF ablation is already overused. Both the U.S. STOP AF trial ...

Apr 1st, 2020 - Anticoagulation for nonvalvular AF is managed with one of the DOAC agents. Currently available DOAC agents include factor Xa inhibitors (apixaban, edoxaban, or rivaroxaban) and the direct thrombin inhibitor dabigatran. DOAC agents can be initiated...

Feb 11th, 2020 - Randomized data provide equal support for pharmacological and electrical cardioversion of acute atrial fibrillation (AF), but also point to a potential advantage for the drug-first strategy in younger patients and those with first AF episodes. Con...

Dec 12th, 2019 - For the week ending Dec 13, 2019 John Mandrola, MD, comments on the following cardiology news stories: EXCEL Leaders Answer Back After BBC Exposé European Left Main Guidelines in Disarray After EXCEL Cover-up Alleged FDA Panel Rejects Vernakalant ...

Dec 11th, 2019 - A Food and Drug Administration advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial fibrillation (AFib). It was the second time before an.